Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Probióticos profilácticos para prematuros de peso extremadamente bajo al nacer (PROPEL)

23 de octubre de 2026 actualizado por: Thomas Abrahamsson, MD, PhD, Ostergotland County Council, Sweden

Mortality and incidence of severe complications is still high among extremely premature infants. Common causes of severe complications in this population are poor nutrition, necrotizing enterocolitis, and severe infections. Feeding intolerance is also a common problem resulting in prolonged need for intravenous lines and poor nutrition.

The aim of the study is to evaluate whether supplementation with the probiotic bacterium Lactobacillus reuteri DSM 17938 daily to premature infants with extremely low birth weight increases feeding tolerance to breast milk and thereby improves nutrition, increases growth and reduces serious complications and mortality in this population. Follow ups will be conducted at 2. 5,5- and 14 years of age for evaluating neurodevelopment, lung function and physical fitness. Beyond this, possible mechanisms underlying these effects will be analyzed in stool, breast milk and blood samples.

Descripción general del estudio

Estado

Activo, no reclutando

Condiciones

Intervención / Tratamiento

Descripción detallada

RATIONALE Mortality and incidence of severe complications is still high among extremely premature infants. Common causes of severe complications in this population are poor nutrition, necrotizing enterocolitis (NEC), and severe infections. Feeding intolerance is also a common problem resulting in prolonged need for intravenous lines and poor nutrition. There is scientific evidence that dietary supplements with probiotics may have an effect on these manifestations.

Lactobacillus reuteri is a well studied probiotic bacterium that has been tested in several clinical studies in premature infants and older children, and the results of these studies and animal studies suggest that this bacterium may also have an effect on growth and mortality in extremely premature infants. Lactobacillus reuteri reduces colonization with pathogenic microbes, stimulates gastric and intestinal motility and shortens hospital stay in moderately premature infants. In animal models, L. reuteri also induces anti-inflammatory immune responses, reduces the symptoms of inflammatory bowel disease and the incidence of NEC. Administration of L. reuteri also improves the intestinal barrier both in human studies in children and in animal studies. Dietary supplements of L. reuteri to extremely premature infants may therefore improve feeding tolerance and nutrition and reduce the incidence of severe complications during the neonatal period and later in childhood in this population.

HYPOTHESIS Primary: premature infants with extremely low birth weight receiving daily supplements of Lactobacillus reuteri DSM 17938 will reach full enteral feeding faster compared with children receiving placebo.

STUDY DESIGN This study will be conducted as a prospective multi-center double blind placebo-controlled study in neonatal intensive care units in Sweden. In total 134 neonates with extremely low birth weight (<1000g) and gestational age <28+0 weeks will be randomized to receive either dietary supplements of Lactobacillus reuteri or placebo. Study product will be identical to the active and placebo group besides the addition of Lactobacillus reuteri (1.25 x 100 million bacteria=0.2 ml oil drops per day) in the active group. The supplementation will commence within 1-3 days after birth and will be given daily until gestational week 36+0. The infants will be followed until gestational week 36+0 and data on feeding tolerance, nutrition, growth, infections, NEC, bronchopulmonary dysplasia, death, and potential confounders will be entered in an individual study protocol. Stool, breast milk, and blood samples will be collected for analyses of possible underlying mechanisms.

A 2- and 5.5- year follow up including examination by pediatrician, growth parameters, questionnaire and psychology testing will be performed.

A 14-year follow up will be performed with lung function tests and test for physical fitness.

Tipo de estudio

Intervencionista

Inscripción (Actual)

134

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Linköping, Suecia, 581 85
        • Crown Princess Victoria Chilkdren´s Hopstial, University Hospital
      • Norrköping, Suecia, 60379
        • Vrinnevi Hospital in Norrköping
      • Stockholm, Suecia, SE-171 76
        • Karolinska

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

1 día a 3 días (Niño)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Birth weight < 1000 g
  • Gestational age: v23+0-V27 +6.
  • Age < 72 hours at inclusion.
  • Signed informed consent by parents.

Exclusion Criteria:

  • Fatal or complex congenital malformation at inclusion time.
  • Chromosomal defect at inclusion time.
  • No realistic hope of survival at inclusion time.
  • Gastrointestinal malformation at inclusion time.
  • Participation in another study which aims to influence nutrition, growth, feeding tolerance or necrotizing enterocolitis.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Prevención
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Cuadruplicar

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador activo: Lactobacillus reuteri

Lactobacillus reuteri DSM 17938, 125 million bacteria/day

Oil drops with Lactobacillus reuteri DSM 17938, 125 million bacteria=0.2 ml per day

Comparador de placebos: Placebo

The same oil drops as the active study product but without Lactobacillus reuteri

Oil drops without Lactobacillus reuteri

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Time to Establish Full Enteral Feeds
Periodo de tiempo: Birth to gestational week 36+0

The age of the infants in days when the infant receive 150 ml/kg/day via enteral feeding for the first time.

Birth to gestational week 36+0

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Número de taburetes
Periodo de tiempo: Grabado durante las primeras cuatro semanas.
Grabado durante las primeras cuatro semanas.
Mortalidad
Periodo de tiempo: Nacimiento a gw 36+0
Nacimiento a gw 36+0
Days With Halted Feeding Due to Food Intolerance
Periodo de tiempo: Birth to gestational week 36

Episode with food intolerance. Retention volume> food volume given the last 2 hours (retention checked routinely every 4 hours) and/or clinical signs consistent with necrotizing enterocolitis (reduced general condition and inflated abdomen). The number of such events will also be indicated.

Birth to gestational week 36
Time Until Birth Weight is Regained. Specifies the Number of Full Days the Child Has Lived.
Periodo de tiempo: Birth to gw 36+0

Specifies the number of full days the child has lived.

Birth to gw 36+0
Weight Gain (SD)
Periodo de tiempo: At 14th day of life

In this analysis, the difference in standard deviation score (delta z-scores) for weight, height and head circumference at birth and 14 and 28 days and gestational week 36+0 will be calculated. At gestational week 36+0 also absolute values will be analyzed. A positive delta z-score indicates faster growth than the growth chart would predict.

At 14th day of life
Necrotizing Enterocolitis
Periodo de tiempo: Birth to gw 36+0

Bell´s criteria II-III

Birth to gw 36+0
Sepsis
Periodo de tiempo: Birth to gw 36+0

Blood culture positive sepsis

Birth to gw 36+0
Bronchopulmonary Dysplasia
Periodo de tiempo: Gw 36+0

Need of oxygen or CPAP/ventilator at gw 36+0

Gw 36+0
Weight Gain (SD)
Periodo de tiempo: At 28th day of life

In this analysis, the difference in standard deviation score (delta z-scores) for weight, height and head circumference at birth and 14 and 28 days and gestational week 36+0 will be calculated. At gestational week 36+0 also absolute values will be analyzed. A positive delta z-score indicates faster growth than the growth chart would predict.

At 28th day of life
Weight Gain (SD)
Periodo de tiempo: At gestational week 36+0

In this analysis, the difference in standard deviation score (delta z-scores) for weight, height and head circumference at birth and 14 and 28 days and gestational week 36+0 will be calculated. At gestational week 36+0 also absolute values will be analyzed. A positive delta z-score indicates faster growth than the growth chart would predict.

At gestational week 36+0
Length Gain (SD)
Periodo de tiempo: At 14th day of life

In this analysis, the difference in standard deviation score (delta z-scores) for weight, height and head circumference at birth and 14 and 28 days and gestational week 36+0 will be calculated. At gestational week 36+0 also absolute values will be analyzed. A positive delta z-score indicates faster growth than the growth chart would predict.

At 14th day of life
Length Gain (SD)
Periodo de tiempo: At 28th day of life

In this analysis, the difference in standard deviation score (delta z-scores) for weight, height and head circumference at birth and 14 and 28 days and gestational week 36+0 will be calculated. At gestational week 36+0 also absolute values will be analyzed. A positive delta z-score indicates faster growth than the growth chart would predict.

At 28th day of life
Length Gain (SD)
Periodo de tiempo: At gestational week 36+0

In this analysis, the difference in standard deviation score (delta z-scores) for weight, height and head circumference at birth and 14 and 28 days and gestational week 36+0 will be calculated. At gestational week 36+0 also absolute values will be analyzed. A positive delta z-score indicates faster growth than the growth chart would predict.

At gestational week 36+0
Head Circumference Growth (SD)
Periodo de tiempo: At 14th day of life

In this analysis, the difference in standard deviation score (delta z-scores) for weight, height and head circumference at birth and 14 and 28 days and gestational week 36+0 will be calculated. At gestational week 36+0 also absolute values will be analyzed. A positive delta z-score indicates faster growth than the growth chart would predict.

At 14th day of life
Head Circumference Growth (SD)
Periodo de tiempo: At 28th day of life

In this analysis, the difference in standard deviation score (delta z-scores) for weight, height and head circumference at birth and 14 and 28 days and gestational week 36+0 will be calculated. At gestational week 36+0 also absolute values will be analyzed. A positive delta z-score indicates faster growth than the growth chart would predict.

At 28th day of life
Head Circumference Growth (SD)
Periodo de tiempo: At gestational week 36+0

In this analysis, the difference in standard deviation score (delta z-scores) for weight, height and head circumference at birth and 14 and 28 days and gestational week 36+0 will be calculated. At gestational week 36+0 also absolute values will be analyzed. A positive delta z-score indicates faster growth than the growth chart would predict.

At gestational week 36+0
Neurological Development 2y
Periodo de tiempo: At 2 years corrected age

Bayleys´s test by psychologist

At 2 years corrected age
Neurological Development Impairment
Periodo de tiempo: At 2 years corrected age

A composite of several outcomes: impaired cognition at the Bayleys´test, cerebral palsy, blindness and deafness, divided into normal, mild, moderate and severe. Mild -1SD to -2SD, Moderate <-2D to 3 SD and Severe <3SD

At 2 years corrected age
Neurodevelopmental Impairment at 5y
Periodo de tiempo: 5.5 years of age +/-6 months

Wechsler Preschool and Primary Scale of Intelligence (WPPSI) by psychologist; Cerebral Palsy by physician and physiotherapist: vision by ophtalmologist, deafness by audiologist. The diagnoses will be measured both separately and collectively as a composite, neurodevelopment impairment (NDI). A total WPPSI will be calculatated as continuous data, whereas the other variables will be dichotomized

5.5 years of age +/-6 months
Lung Function at 14 y
Periodo de tiempo: 14 years of age +/-6 months

Lung function assessed with dynamic and static spirometry, Impulse oscillomtry (IOS), and Diffusing capacity of the lungs for carbon monoxide (DLCO). To distinguish between allergic asthma and non-allergic lung impairment, allergen specific IgE will be measured together with an allergy questionnaire.

14 years of age +/-6 months
Physical Fitness at 14y
Periodo de tiempo: 14 years of age +/-6 months

Physical fitness will assessed with three measures: long standing jump, hand grip strength, and 20 m beep test

14 years of age +/-6 months
Anthrometry at 14y
Periodo de tiempo: 14 years f age +/-6 months

Weight, length, head circumference, and body composition with an impedance scale

14 years f age +/-6 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Colaboradores

Investigadores

  • Investigador principal: Thomas Abrahamsson, MD, PhD, Linköping University Hospital; County Council of Östergötland

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

1 de junio de 2012

Finalización primaria (Actual)

1 de diciembre de 2015

Finalización del estudio (Estimado)

1 de diciembre de 2029

Fechas de registro del estudio

Enviado por primera vez

18 de mayo de 2012

Primero enviado que cumplió con los criterios de control de calidad

21 de mayo de 2012

Publicado por primera vez (Estimado)

22 de mayo de 2012

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

13 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

23 de octubre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • Dnr 2012/28-31

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .